FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140799056> ?p ?o ?g. }

• W2140799056 endingPage "2104" @default.
• W2140799056 startingPage "2088" @default.
• W2140799056 abstract "Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the first choice for empiric therapy of acute uncomplicated urinary tract infection (UTI) in women. In areas where resistance to TMP/SMX is known to be high, ciprofloxacin and other fluoroquinolones are recommended as first-line choices for the empiric therapy of UTI.This study compared the efficacy and safety profile of once-daily extended-release ciprofloxacin 500 mg (referred to hereafter as ciprofloxacin QD) with those of conventional ciprofloxacin 250 mg BID, each administered orally for 3 days, in the treatment of uncomplicated UTI in women.In this multicenter, prospective, randomized, double-blind, double-dummy, Phase III trial, adult women with clinical signs and symptoms of acute uncomplicated UTI, pyuria, and a positive pretherapy urine culture (>/=10(5) colony-forming units/mL) received ciprofloxacin QD or ciprofloxacin BID. Bacteriologic and clinical outcomes were assessed at the test-of-cure visit (4-11 days after completion of therapy) and the late follow-up visit (25-50 days after completion of therapy).The intent-to-treat population consisted of 891 patients (444 ciprofloxacin QD, 447 ciprofloxacin BID); 422 patients were evaluable for efficacy (199 ciprofloxacin QD, 223 ciprofloxacin BID). At the test-of-cure visit, bacteriologic eradication was achieved in 94.5% (188/199) of the ciprofloxacin QD group and 93.7% (209/223) of the ciprofloxacin BID group (95% CI, -3.5 to 5.1). Clinical cure was achieved in 95.5% (189/198) of the ciprofloxacin QD group and 92.7% (204/220) of the ciprofloxacin BID group (95% CI, -1.6 to 7.1). Bacteriologic and clinical outcomes at the late follow-up visit were consistent with the test-of-cure findings. The rate of eradication of Escherichia coli, the most prevalent organism, was >97% in each treatment group. Rates of drug-related adverse events were similar with the once- and twice-daily ciprofloxacin regimens (10% and 9%, respectively).Extended-release ciprofloxacin 500 mg given once daily for 3 days was as effective and well tolerated as conventional ciprofloxacin 250 mg given twice daily for 3 days in the treatment of acute uncomplicated UTI in women." @default.
• W2140799056 created "2016-06-24" @default.
• W2140799056 creator A5010618777 @default.
• W2140799056 creator A5013136477 @default.
• W2140799056 creator A5045124150 @default.
• W2140799056 creator A5076511543 @default.
• W2140799056 creator A5081934344 @default.
• W2140799056 creator A5086136338 @default.
• W2140799056 creator A5086752915 @default.
• W2140799056 creator A5091425034 @default.
• W2140799056 date "2002-12-01" @default.
• W2140799056 modified "2023-09-28" @default.
• W2140799056 title "Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women" @default.
• W2140799056 cites W127997916 @default.
• W2140799056 cites W1989051873 @default.
• W2140799056 cites W1995013130 @default.
• W2140799056 cites W2005883348 @default.
• W2140799056 cites W2017210944 @default.
• W2140799056 cites W2032438162 @default.
• W2140799056 cites W2037239538 @default.
• W2140799056 cites W2037554663 @default.
• W2140799056 cites W2052619562 @default.
• W2140799056 cites W2073144086 @default.
• W2140799056 cites W2079785911 @default.
• W2140799056 cites W2090461572 @default.
• W2140799056 cites W2101388903 @default.
• W2140799056 cites W2108588625 @default.
• W2140799056 cites W2113664107 @default.
• W2140799056 cites W2117115851 @default.
• W2140799056 cites W2131891465 @default.
• W2140799056 cites W2149825535 @default.
• W2140799056 cites W2168922969 @default.
• W2140799056 cites W2170027182 @default.
• W2140799056 cites W2218339242 @default.
• W2140799056 cites W4248085432 @default.
• W2140799056 cites W4301458124 @default.
• W2140799056 doi "https://doi.org/10.1016/s0149-2918(02)80099-6" @default.
• W2140799056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12581547" @default.
• W2140799056 hasPublicationYear "2002" @default.
• W2140799056 type Work @default.
• W2140799056 sameAs 2140799056 @default.
• W2140799056 citedByCount "64" @default.
• W2140799056 countsByYear W21407990562012 @default.
• W2140799056 countsByYear W21407990562013 @default.
• W2140799056 countsByYear W21407990562014 @default.
• W2140799056 countsByYear W21407990562015 @default.
• W2140799056 countsByYear W21407990562016 @default.
• W2140799056 countsByYear W21407990562017 @default.
• W2140799056 countsByYear W21407990562018 @default.
• W2140799056 countsByYear W21407990562020 @default.
• W2140799056 countsByYear W21407990562021 @default.
• W2140799056 countsByYear W21407990562022 @default.
• W2140799056 crossrefType "journal-article" @default.
• W2140799056 hasAuthorship W2140799056A5010618777 @default.
• W2140799056 hasAuthorship W2140799056A5013136477 @default.
• W2140799056 hasAuthorship W2140799056A5045124150 @default.
• W2140799056 hasAuthorship W2140799056A5076511543 @default.
• W2140799056 hasAuthorship W2140799056A5081934344 @default.
• W2140799056 hasAuthorship W2140799056A5086136338 @default.
• W2140799056 hasAuthorship W2140799056A5086752915 @default.
• W2140799056 hasAuthorship W2140799056A5091425034 @default.
• W2140799056 hasConcept C126322002 @default.
• W2140799056 hasConcept C141071460 @default.
• W2140799056 hasConcept C168563851 @default.
• W2140799056 hasConcept C2775886723 @default.
• W2140799056 hasConcept C2778512257 @default.
• W2140799056 hasConcept C2908647359 @default.
• W2140799056 hasConcept C501593827 @default.
• W2140799056 hasConcept C535046627 @default.
• W2140799056 hasConcept C71924100 @default.
• W2140799056 hasConcept C77411442 @default.
• W2140799056 hasConcept C86803240 @default.
• W2140799056 hasConcept C89423630 @default.
• W2140799056 hasConcept C99454951 @default.
• W2140799056 hasConceptScore W2140799056C126322002 @default.
• W2140799056 hasConceptScore W2140799056C141071460 @default.
• W2140799056 hasConceptScore W2140799056C168563851 @default.
• W2140799056 hasConceptScore W2140799056C2775886723 @default.
• W2140799056 hasConceptScore W2140799056C2778512257 @default.
• W2140799056 hasConceptScore W2140799056C2908647359 @default.
• W2140799056 hasConceptScore W2140799056C501593827 @default.
• W2140799056 hasConceptScore W2140799056C535046627 @default.
• W2140799056 hasConceptScore W2140799056C71924100 @default.
• W2140799056 hasConceptScore W2140799056C77411442 @default.
• W2140799056 hasConceptScore W2140799056C86803240 @default.
• W2140799056 hasConceptScore W2140799056C89423630 @default.
• W2140799056 hasConceptScore W2140799056C99454951 @default.
• W2140799056 hasIssue "12" @default.
• W2140799056 hasLocation W21407990561 @default.
• W2140799056 hasLocation W21407990562 @default.
• W2140799056 hasOpenAccess W2140799056 @default.
• W2140799056 hasPrimaryLocation W21407990561 @default.
• W2140799056 hasRelatedWork W1586374228 @default.
• W2140799056 hasRelatedWork W2003938723 @default.
• W2140799056 hasRelatedWork W2047967234 @default.
• W2140799056 hasRelatedWork W2089201504 @default.
• W2140799056 hasRelatedWork W2118496982 @default.
• W2140799056 hasRelatedWork W2364998975 @default.

• next